No material signal from this cluster, activity aligns with routine equity compensation management. Traders should monitor for any follow-up open-market sales by additional insiders or changes in guidance.
TEVA drugs
TEVA drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 26 $33.75entry
- T+1 · 9mo ago +0.24%α +0.69% · $33.83
- T+5 · 9mo ago −5.93%α −4.80% · $31.75
- T+20 · 8mo ago −11.82%α −5.42% · $29.76
- T+60 · 6mo ago +1.23%α −6.52% · $34.16
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Multiple Teva executives, including the CEO, CFO, and other C-suite officers, exercised stock options and received share grants in a routine compensation-related cluster. EVP Matthew Shields conducted open-market sales totaling $547.7K, representing full disposal of shares acquired through option exercises. All other transactions were non-cash events related to equity compensation.
Key Financial Metrics
Key Facts
- EVP Matthew Shields sold 17,295 shares for $547.7K in open-market transactions following option exercises.
- CEO Francis Richard D, CFO Kalif Eliyahu Sharon, and other executives exercised options and received share grants totaling over 300,000 shares, all non-cash events.
- All transactions except Shields' sale were non-cash (codes M, A) and part of standard equity compensation execution.
- Total open-market sales in cluster: $547.7K, representing 0.0015% of Teva's $35.7B market cap, negligible relative to company size.
Financial Impact
$547.7K in open-market sales by one executive; no material financial impact from non-cash transactions
Risk Factors
- Perception risk if media misinterprets option exercise and sale as negative sentiment, though common for executives to sell shares post-exercise for diversification.
- Potential for increased selling pressure if more executives follow similar patterns in coming weeks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (20 trades, 7d window) | cluster-TEVA-1773086773969 |
Track record
61 reports on TEVA
6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 15 of 17 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $42.57 −1.37% settles Feb 12
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $42.57 −2.47% settles Feb 10
- Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $42.57 −1.55% settles Feb 9
- Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $42.57 −0.09% settles Feb 4
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers